R-etodolac is a more potent Wnt signaling inhibitor than enantiomer, S-etodolac

JoAnn S. Roberts(University of California, Los Angeles), Jie Zheng(Fifth Tianjin Central Hospital), Christiana S. Han(University of California, Los Angeles), Sarah Robertson(University of California, Los Angeles), Chao Ma(Shimadzu (China)), Sunyu Kang(Harvard University), Sophie X. Deng(Cornea Eye Institute)
Biochemistry and Biophysics Reports
February 19, 2022
10.1016/j.bbrep.2022.101231
Cited by 6

Related Papers

Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
|New England Journal of Medicine|2013|3.4k
Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial
|The Lancet Oncology|2015|1.6k
Evaluation of Immune-Related Response Criteria and RECIST v1.1 in Patients With Advanced Melanoma Treated With Pembrolizumab
|Journal of Clinical Oncology|2016|754
Programmed Death-Ligand 1 Expression and Response to the Anti–Programmed Death 1 Antibody Pembrolizumab in Melanoma
|Journal of Clinical Oncology|2016|679
PDZ domains and their binding partners: structure, specificity, and modification
|Cell Communication and Signaling|2010|582